Cheryl Grant
Psychiatric/Mental Health · New Castle, DENPI 1821530197
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alkermes, Inc. at 24.9% of the total. Reporting peaked in 2021 at $882 and has fallen 95.6% since, to $39 in 2025.
Across 96 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$527
- Johnson & Johnson$431
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$322
- AbbVie$274
- Otsuka America Pharmaceutical, Inc.$232
- Neurocrine Biosciences, Inc.$104
- plus $229 from 5 others
What the payments were for
- Food & beverage$2,06397%
- Education$553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 22 | $527 |
| Johnson & Johnson | 21 | $431 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $322 |
| AbbVie | 12 | $274 |
| Otsuka America Pharmaceutical, Inc. | 12 | $232 |
| Neurocrine Biosciences, Inc. | 4 | $104 |
| Sunovion Pharmaceuticals Inc. | 6 | $91 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Indivior Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$487
- ARISTADA INITIO$122
- CAPLYTA$100
How this compares
$2,119 in reported general payments places this provider in the 75th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 15 | $475 |
| Duloxetine Hcl | 12 | $470 |
| Quetiapine Fumarate | 13 | $156 |
| Lisinopril | 13 | $119 |
| Trazodone Hcl | 30 | $97 |
| Alprazolam | 13 | $86 |
| Omeprazole | 12 | $74 |
| Escitalopram Oxalate | 12 | $63 |
| Gabapentin | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in New Castle
- Michael KolodgieNew Castle$3K
- Guirlene ClervoixNew Castle$3K
- Oluwadamilare ShoneyeNew Castle$3K
- Tracee SherlockNew Castle$2K
- Ronald TyreeWilmington$59K
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
- Kameka HartNewark$10K
- Jenika MilesWilmington$8K
- Catherine DotyNewport$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.